HERON THERAPEUTICS, INC. /DE/ Defined Contribution Plan, Cost
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Defined Contribution Plan, Cost of $800.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-26
- HERON THERAPEUTICS, INC. /DE/ defined contribution plan, cost for fiscal 2025 was $800.00K, a 14.29% increase from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ defined contribution plan, cost for fiscal 2024 was $700.00K, a 30.00% decline from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ defined contribution plan, cost for fiscal 2023 was $1.00M, a 28.57% decline from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ defined contribution plan, cost for fiscal 2022 was $1.40M, a 7.69% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $800.00K 10-K · filed 2026-02-26 | |
| 2024-12-31 | $700.00K 10-K · filed 2026-02-26 | |
| 2023-12-31 | $1.00M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $1.40M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $1.30M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $1.10M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $1.00M 10-K · filed 2022-02-28 | |
| 2018-12-31 | $700.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $600.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $600.00K 10-K · filed 2019-02-22 | |
| 2015-12-31 | $300.00K 10-K · filed 2018-02-27 | $251.00K 10-K · filed 2016-02-19 |
| 2014-12-31 | $200.00K 10-K · filed 2017-02-23 | $181.00K 10-K · filed 2015-03-13 |
| 2013-12-31 | $134.00K 10-K · filed 2016-02-19 | |
| 2012-12-31 | $71.00K 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |